All In Biotech

NDA 212028 · Eisai INC

Dayvigo

Lemborexant · Oral · Orexin Receptor Antagonist

Novel

Last checked: Nov 20, 2026Latest source record: Feb 19, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Dec 20, 2019

Approved uses

2

Original approval plus efficacy supplements

Registered trials

48

7 Phase 3, 11 recruiting

FAERS reports

2,946

2,287 serious, 370 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 24, 2025.

DAYVIGO is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance [see Clinical Studies ( 14.1 )] . DAYVIGO is an orexin receptor antagonist indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. ( 1 )

Mechanism: The mechanism of action of lemborexant in the treatment of insomnia is presumed to be through antagonism of orexin receptors. The orexin neuropeptide signaling system plays a role in wakefulness. Blocking the binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R is thought to suppress wake drive.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • DAYVIGO · LEMBOREXANT 10MG · TABLET, ORAL · Prescription
  • DAYVIGO · LEMBOREXANT 5MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Lemborexant" as an intervention, any sponsor and status, largest first.

All 48 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective332
  • off label use215
  • suicide attempt175
  • condition aggravated157
  • suicidal ideation156
  • somnolence149
  • fall111
  • nausea104
  • dizziness97
  • headache97
  • insomnia94
  • adverse drug reaction92

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20151
20181
20192
2020199
2021320
2022376
2023420
2024554
2025604
2026469

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Dayvigo (Lemborexant)

2024 spending

$21.0M

Beneficiaries

14,593

57,890 claims

Per beneficiary

$1,437

$11.03 per unit

View as table
YearSpending
2020$1,189,295
2021$9,100,845
2022$13,911,430
2023$16,516,063
2024$20,975,238

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 79 on PubMed

Sponsor: Eisai

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.